Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-30T21:41:09.999Z Has data issue: false hasContentIssue false
  • English
  • Français

Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial

Published online by Cambridge University Press:  16 April 2013

L. Clausen ,
C. R. Hjorthøj ,
A. Thorup ,
P. Jeppesen ,
L. Petersen ,
M. Bertelsen  and
M. Nordentoft
L. Clausen
Affiliation:
Psychiatric Center Copenhagen, Copenhagen University, Faculty of Health Sciences, Copenhagen, Denmark
C. R. Hjorthøj
Affiliation:
Psychiatric Center Copenhagen, Copenhagen University, Faculty of Health Sciences, Copenhagen, Denmark
A. Thorup
Affiliation:
Psychiatric Center Copenhagen, Copenhagen University, Faculty of Health Sciences, Copenhagen, Denmark
P. Jeppesen
Affiliation:
Psychiatric Center Copenhagen, Copenhagen University, Faculty of Health Sciences, Copenhagen, Denmark
L. Petersen
Affiliation:
Psychiatric Center Copenhagen, Copenhagen University, Faculty of Health Sciences, Copenhagen, Denmark
M. Bertelsen
Affiliation:
Psychiatric Center Copenhagen, Copenhagen University, Faculty of Health Sciences, Copenhagen, Denmark
M. Nordentoft*
Affiliation:
Psychiatric Center Copenhagen, Copenhagen University, Faculty of Health Sciences, Copenhagen, Denmark
*
* Address for correspondence: Dr M. Nordentoft, Psychiatric Center Copenhagen, Bispebjerg Bakke 23, 2400 Copenhagen NV, Denmark. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Several studies indicate that cannabis use among patients with psychotic disorders is associated with worse outcome, but only a few studies have controlled for baseline condition and medication.

Method

At 5-year follow-up, interviews were carried out with 314 first-episode psychosis patients included in the OPUS trial. The patients included were in the age range of 18 to 45 years old and 59% were male. Cannabis use was extracted from the Schedule for Clinical Assessment in Neuropsychiatry. At follow-up, the patients were divided into different groups according to the variable cannabis use: abstainers, stoppers, starters and continuers. Psychotic, negative and disorganized dimensions (ranging from zero to five) were calculated for each of the four groups based on the Schedule for the Assessment of Positive and Negative Symptoms in Schizophrenia.

Results

Cannabis users were younger (24.6 years v. 27.4 years, p < 0.001) and had a lower level of education. At the 5-year follow-up, users of cannabis had higher scores on the psychotic dimension [difference 0.97, 95% confidence interval (CI) 0.41–1.53, p = 0.001] and lower levels of the Global Assessment of Functioning (difference 8.26, 95% CI 2.13–14.39, p = 0.01). Those who stopped using cannabis between entry and 5-year follow-up had a significantly lower level of psychotic symptoms at 5-year follow-up even after controlling for baseline level of psychotic symptoms and for insufficient antipsychotic medication (adjusted difference in psychotic dimension –1.04, 95% CI –1.77 to –0.31, p = 0.006).

Conclusions

Continuous cannabis use was associated with higher levels of psychotic symptoms after 5 years, and this association was only partly explained by insufficient antipsychotic medication.

Keywords

Cannabiscohortfollow-upmedicationpsychosis
Type
Original Articles
Information
Psychological Medicine , Volume 44 , Issue 1 , January 2014 , pp. 117 - 126
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andreasen, NC, Carpenter, WT Jr, Kane, JM, Lasser, RA, Marder, SR, Weinberger, DR (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry 162, 441–449.Google Scholar
Anglin, DM, Corcoran, CM, Brown, AS, Chen, H, Lighty, Q, Brook, JS, Cohen, PR (2012). Early cannabis use and schizotypal personality disorder symptoms from adolescence to middle adulthood. Schizophrenia Research 137, 45–49.Google Scholar
Archie, S, Rush, BR, Akhtar-Danesh, N, Norman, R, Malla, A, Roy, P, Zipursky, RB (2007). Substance use and abuse in first-episode psychosis: prevalence before and after early intervention. Schizophrenia Bulletin 33, 1354–1363.Google Scholar
Arndt, S, Andreasen, NC, Flaum, M, Miller, D, Nopoulos, P (1995). A longitudinal study of symptom dimensions in schizophrenia. Prediction and patterns of change. Archives of General Psychiatry 52, 352–360.CrossRefGoogle ScholarPubMed
Bertelsen, M, Jeppesen, P, Petersen, L, Thorup, A, Ohlenschlaeger, J, le Quach, P, Christensen, TO, Krarup, G, Jorgensen, P, Nordentoft, M (2008). Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Archives of General Psychiatry 65, 762–771.Google Scholar
Cannon-Spoor, E, Potkin, SG, Wyatt, RJ (1982). Measurement of premorbid adjustment in chronic schizophrenia. Schizophrenia Bulletin 8, 470–484.Google Scholar
Compton, MT, Kelley, ME, Ramsay, CE, Pringle, M, Goulding, SM, Esterberg, ML, Stewart, T, Walker, EF (2009). Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. American Journal of Psychiatry 166, 1251–1257.Google Scholar
D'Souza, DC, bi-Saab, WM, Madonick, S, Forselius-Bielen, K, Doersch, A, Braley, G, Gueorguieva, R, Cooper, TB, Krystal, JH (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 57, 594–608.Google Scholar
Di Forti, M, Morgan, C, Dazzan, P, Pariante, C, Mondelli, V, Marques, TR, Handley, R, Luzi, S, Russo, M, Paparelli, A, Butt, A, Stilo, SA, Wiffen, B, Powell, J, Murray, RM (2009). High-potency cannabis and the risk of psychosis. British Journal of Psychiatry 195, 488–491.CrossRefGoogle ScholarPubMed
Dragt, S, Nieman, DH, Schultze-Lutter, F, van der Meer, F, Becker, H, de Haan, L, Dingemans, PM, Birchwood, M, Patterson, P, Salokangas, RK, Heinimaa, M, Heinz, A, Juckel, G, Graf von Reventlow, H, French, P, Stevens, H, Ruhrmann, S, Klosterkötter, J, Linszen, DH (2012). Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. Acta Psychiatrica Scandinavica 125, 45–53.Google Scholar
Dunn, M, O'Driscoll, C, Dayson, D, Wills, W, Leff, J (1990). The TAPS Project. 4: An observational study of the social life of long-stay patients. British Journal of Psychiatry 157, 842–8, 852.Google Scholar
Faridi, K, Joober, R, Malla, A (2012). Medication adherence mediates the impact of sustained cannabis use on symptom levels in first-episode psychosis. Schizophrenia Research 141, 78–82.CrossRefGoogle ScholarPubMed
Häfner, H, Riecher-Rössler, A, Hambrecht, M, Maurer, K, Meissner, S, Schmidtke, A, Fätkenheuer, B, Löffler, W, van der Heiden, W (1992). IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophrenia Research 6, 209–223.CrossRefGoogle ScholarPubMed
Hjorthoj, CR, Fohlmann, A, Larsen, AM, Arendt, M, Nordentoft, M (2012 a). Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial. Addiction 107, 1123–1131.CrossRefGoogle ScholarPubMed
Hjorthoj, CR, Hjorthoj, AR, Nordentoft, M (2012 b). Validity of Timeline Follow-Back for self-reported use of cannabis and other illicit substances – systematic review and meta-analysis. Addictive Behavior 37, 225–233.Google Scholar
Jeppesen, P, Petersen, L, Thorup, A, Abel, MB, Ohlenschlaeger, J, Christensen, TO, Krarup, G, Jorgensen, P, Nordentoft, M (2008). The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis. Psychological Medicine 38, 1157–1166.CrossRefGoogle ScholarPubMed
Kamali, M, Kelly, BD, Clarke, M, Browne, S, Gervin, M, Kinsella, A, Lane, A, Larkin, C, O'Callaghan, E (2006). A prospective evaluation of adherence to medication in first episode schizophrenia. European Psychiatry 21, 29–33.Google Scholar
Large, M, Sharma, S, Compton, MT, Slade, T, Nielssen, O (2011). Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Archives of General Psychiatry 68, 555–561.CrossRefGoogle ScholarPubMed
Larsen, TK, Friis, S, Haahr, U, Johannessen, JO, Melle, I, Opjordsmoen, S, Rund, BR, Simonsen, E, Vaglum, PV, McGlashan, TH (2004). Premorbid adjustment in first-episode non-affective psychosis: distinct patterns of pre-onset course. British Journal of Psychiatry 185, 108–115.Google Scholar
Macleod, J, Oakes, R, Copello, A, Crome, I, Egger, M, Hickman, M, Oppenkowski, T, Stokes-Lampard, H, Davey, SG (2004). Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 363, 1579–1588.Google Scholar
McGrath, J, Welham, J, Scott, J, Varghese, D, Degenhardt, L, Hayatbakhsh, MR, Alati, R, Williams, GM, Bor, W, Najman, JM (2010). Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Archives of General Psychiatry 67, 440–447.CrossRefGoogle Scholar
Miller, R, Ream, G, McCormack, J, Gunduz-Bruce, H, Sevy, S, Robinson, D (2009). A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophrenia Research 113, 138–144.Google Scholar
Moore, THM, Zammit, S, Lingfjord.Hughes, A, Barnes, TRE, Jones, PB, Lewis, G (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319–328.Google Scholar
Mors, O, Perto, GP, Mortensen, PB (2011). The Danish psychiatric central research register. Scandinavian Journal of Public Health 39, 54–57.Google Scholar
Nelson, HE (1982). National Adult Reading Test (NART). NFER-Nelson: Windsor.Google Scholar
Nordentoft, M, Ohlenschlaeger, J, Thorup, A, Petersen, L, Jeppesen, P, Bertelsen, M (2010). Deinstitutionalization revisited: a 5-year follow-up of a randomized clinical trial of hospital-based rehabilitation versus specialized assertive intervention (OPUS) versus standard treatment for patients with first-episode schizophrenia spectrum disorders. Psychological Medicine 40, 1619–1626.Google Scholar
Nordentoft, M, Pedersen, MG, Pedersen, CB, Blinkenberg, S, Mortensen, PB (2012). The new asylums in the community: severely ill psychiatric patients living in psychiatric supported housing facilities. A Danish register-based study of prognostic factors, use of psychiatric services, and mortality. Social Psychiatry and Psychiatric Epidemiology 47, 1251–1261.Google Scholar
Pedersen, CB, Gotzsche, H, Moller, JO, Mortensen, PB (2006). The Danish Civil Registration System. A cohort of eight million persons. Danish Medical Bulletin 53, 441–449.Google Scholar
Pedersen, G, Hagtvet, KA, Karterud, S (2007). Generalizability studies of the Global Assessment of Functioning-Split version. Comprehensive Psychiatry 48, 88–94.Google Scholar
Petersen, L, Jeppesen, P, Thorup, A, Abel, MB, Ohlenschlaeger, J, Christensen, TO, Krarup, G, Jorgensen, P, Nordentoft, M (2005). A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. British Medical Journal 331, 602.CrossRefGoogle ScholarPubMed
Petersen, L, Jeppesen, P, Thorup, A, Ohlenschlaeger, J, Krarup, G, Ostergard, T, Jorgensen, P, Nordentoft, M (2007). Substance abuse and first-episode schizophrenia-spectrum disorders. The Danish OPUS trial. Early Intervention in Psychiatry 1, 88–96.Google Scholar
Quach, PL, Mors, O, Christensen, TO, Krarup, G, Jorgensen, P, Bertelsen, M, Jeppesen, P, Petersen, L, Thorup, A, Nordentoft, M (2009). Predictors of poor adherence to medication among patients with first-episode schizophrenia-spectrum disorder. Early Intervention in Psychiatry 3, 66–74.Google Scholar
Rubino, T, Zamberletti, E, Parolaro, D (2012). Adolescent exposure to cannabis as a risk factor for psychiatric disorders. Journal of Psychopharmacology 26, 177–188.Google Scholar
Russell, AJ, Munro, J, Jones, PB, Hayward, P, Hemsley, DR, Murray, RM (2000). The National Adult Reading Test as a measure of premorbid IQ in schizophrenia. British Journal of Clinical Psychology 39, 297–305.Google Scholar
Schimmelmann, BG, Conus, P, Cotton, S, Kupferschmid, S, McGorry, PD, Lambert, M (2012). Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis. European Psychiatry 27, 463–469.Google Scholar
Schimmelmann, BG, Conus, P, Cotton, SM, Kupferschmid, S, Karow, A, Schultze-Lutter, F, McGorry, PD, Lambert, M (2011). Cannabis use disorder and age at onset of psychosis – a study in first-episode patients. Schizophrenia Research 129, 52–56.Google Scholar
Sundhedsstyrelsen (2012). Narkosituationen i Danmark 2012 (ed. Sundhedsstyrelsen), pp. 1–117. Sundhedsstyrelsen (Danish National Board of Health): Copenhagen.Google Scholar
Thorup, A, Petersen, L, Jeppesen, P, Ohlenschlaeger, J, Christensen, T, Krarup, G, Jorgensen, P, Nordentoft, M (2005). Integrated treatment ameliorates negative symptoms in first episode psychosis – results from the Danish OPUS trial. Schizophrenia Research 79, 95–105.Google Scholar
van Dijk, D, Koeter, MW, Hijman, R, Kahn, RS, van den Brink, W (2012). Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. Schizophrenia Research 137, 50–57.Google Scholar
WHO (1992). Life Chart Rating Form. Introduction to the Life Chart Schedule. World Health Organization: Geneva.Google Scholar
Wing, JK, Babor, T, Brugha, T, Burke, J, Cooper, JE, Giel, R, Jablenski, A, Regier, D, Sartorius, N (1990). SCAN: Schedule for Clinical Assessment in Neuropsychiatry. Archives of General Psychiatry 47, 589–593.Google Scholar
Zamberletti, E, Prini, P, Speziali, S, Gabaglio, M, Solinas, M, Parolaro, D, Rubino, T (2012). Gender-dependent behavioral and biochemical effects of adolescent delta-9-tetrahydrocannabinol in adult maternally deprived rats. Neuroscience 204, 245–257.Google Scholar
Zammit, S, Moore, TH, Lingford-Hughes, A, Barnes, TR, Jones, PB, Burke, M, Lewis, G (2008). Effects of cannabis use on outcomes of psychotic disorders: systematic review. British Journal of Psychiatry 193, 357–363.Google Scholar
Zammit, S, Owen, MJ, Evans, J, Heron, J, Lewis, G (2011). Cannabis, COMT and psychotic experiences. British Journal of Psychiatry 199, 380–385.Google Scholar